PEAR Therapeutics (PEAR) recently announced it will be partnering with Novartis to develop prescription digital therapeutics for the treatment of schizophrenia and multiple sclerosis (MS). Novartis will offer its expertise in neurological disorder, clinical development, and commercialization.

Together the two companies will seek the approval for PEAR’s THRIVE digital therapeutic, a clinically validated prescription digital therapeutic that applies evidence-based, multi-modal, and reinforcement therapy. It is comprised of a user-facing smartphone application and clinician-facing web interface. PEAR and Novartis will also focus on developing a therapeutic application that alleviates disease burden in individuals with MS.

Prescription . . .

Want To Read More? Log In Or Become A Free Member
Resource Available For All OPEN MINDS Circle Members
If you are already a member, log in to your account to access this resource and more.

You can become a free member and get access now. Learn more about the OPEN MINDS Circle Market Intelligence Service Membership. Reach out to our team at info@openminds.com, or call us at 877-350-6463.

A Paid OPEN MINDS Circle Membership provides unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!

Addiction Treatment Services

Addiction is a chronic disease, which causes individuals to seek “reward” from substance-use or other activities whether or not they may cause harm. Addiction treatment has been in the spotlight as payers, policymakers, and health systems struggle to address the opioid crisis and increasing substance-related mortality rates. As a result, the addiction treatment market is shifting—there is expanded coverage for residential treatment, a push towards greater integration and care coordination, and new competitors entering the market—creating new challenges and opportunities for organizations working in addiction treatment.


Researchers from the Veterans Affairs St. Louis Health Care System found that veterans with type 2 diabetes who were prescribed glucagon-like peptide-1 receptor agonists (GLP-1s) had a lower risk of developing substance use disorders (SUDs) compared to those prescribed sodium-glucose cotransporter-2 (SGLT-2) inhibitors, according to a study published in The BMJ. The study was conducted to examine whether GLP-1 medications—originally developed to treat type 2 diabetes and increasingly used for weight management—are associated with differences… Read